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Abstract. 
Plasmodium falciparum gametocytes develop over 9–12 days while sequestered in deep tissues. On emergence 
into the bloodstream, they circulate for varied amounts of time during which certain host factors might influence 
their further development. We aimed to evaluate the potential association of patient clinical parameters with 
gametocyte development and carriage via in vivo methods. Seventy-two patients were enrolled from three 
hospitals in the Volta region of Ghana in 2016. Clinical parameters were documented for all patients, and 
gametocyte prevalence by microscopy was estimated at 12.5%. By measuring RNA transcripts representing two 
distinct gametocyte developmental stages using reverse transcriptase quantitative PCR (RT-qPCR), we obtained 
a more precise estimate of gametocyte carriage while also inferring gametocyte maturation. Fifty-three percent 
of the study participants harbored parasites expressing transcripts of the immature gametocyte-specific gene 
(PF3D7_1477700), whereas 36% harbored PF3D7_1438800 RNA-positive parasites, which is enriched in mid 
and mature gametocytes, suggesting the presence of more immature stages. Linear logistic regression showed 
that patients older than 5 years but less than 16 years were more likely to carry gametocytes expressing both 
PF3D7_1477700 and PF3D7_1438800 compared with younger participants, and gametocytemia was more 
likely in mildly anemic individuals compared with those with severe/moderate anemia. These data provide 
further evidence that a greater number of malaria patients harbor gametocytes than typically estimated by 
microscopy and suggest a possible association between age, fever, anemia, and gametocytemia. 
INTRODUCTION 
Malaria is one of the most important infectious parasitic diseases and was responsible for 
approximately 445,000 deaths globally from more than 216 million clinical cases in 2016.1 
Among the different malaria parasites, P. falciparum is the most virulent and accounts for 
most malaria-associated mortality and morbidity in sub-Saharan Africa. In the Volta region 
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of Ghana, P. falciparum is the main cause of malaria, and it is the responsible agent in 98% 
of hospitalized malaria patients.2 The parasites are transmitted through the bite of infected 
anopheline mosquitoes, with the pathology resulting from the asexual replication of parasites 
within circulating red blood cells, leading to anemia, disrupted blood flow, and inflammation 
that can be lethal if untreated. The transmission of malaria from humans to mosquitoes is 
mediated by specialized sexual stages called gametocytes, which are derived from asexual 
parasites. Gametocytes of P. falciparum have a prolonged development of 9–12 days, 
maturing through five distinct morphological and metabolic stages. In vivo, stages I–IV are 
sequestered in the spleen and the hematopoietic system and the extravascular space of the 
bone marrow3–6 whereas mature stage V gametocytes are present in peripheral circulation. 
Mature gametocytes circulate in the bloodstream for a varied number of days ranging 1.3–
22.2 days, during which period they are available to biting mosquitoes.7–10 In vitro, 
gametocytes can persist for about 16–32 days.9 
A number of host factors have been linked to gametocyte development and appearance in 
the presence of treatment. Age, hematocrit, hemoglobin genotype, fever, and duration of 
symptoms have all been associated with gametocytemia in treated patients.11–13 In addition, 
drug treatment and host immune responses have been linked with different levels of 
gametocytemia.14–16 In in vitro experiments, specific parasite strains have been associated 
with different levels of gametocyte production and the serum used in gametocyte cultivation, 
suggesting the involvement of parasite genetic factors and host immune factors.17 In addition, 
microvesicles have been shown to mediate communication between malaria parasites, and the 
abundance of these vesicles correlated with high peripheral blood parasitemia18 and 
stimulation of gametocytes in vitro.19,20 Very recently, levels of the host serum factor 
lysophosphatidylcholine were shown to influence rates of sexual differentiation,21 providing 
additional evidence for the influence of host factors on parasite development. 
The involvement of certain parasite genes in gametocyte commitment and production has 
been demonstrated. Notably, the expression of the P. falciparum gametocyte development 1 
protein has been shown to be critical for gametocyte production. Available evidence localizes 
this protein to the nucleus, where it might be involved in regulating gametocyte production 
pathways.22,23 In addition, the transcription factor AP2-G has been identified as a master 
regulator for sexual development, and its expression is controlled epigenetically through the 
incorporation of the silencing histone mark, histone 3 lysine 9 trimethylation (H3K9me3), at 
the ap2-g locus.24,25 
Although both the parasite and host factors are involved in regulating sexual 
differentiation and development, it is not known how these factors directly affect gametocyte 
production in vivo as most human studies have been in treated individuals. It is known that a 
variable percentage of asexual parasites develop into gametocytes, but how this is determined 
and regulated in vivo is not clearly understood, as early gametocyte markers have mainly 
been deployed in studies of cultured P. falciparum.9,10,22 In this study, we measured 
transcripts from two different gametocyte-specific genes as indicators of early and late stages 
of sexual development, respectively, and related gene expression to patient clinical 
parameters. As previously described,26 these parasite stage-specific genes were selected 
based on their stage specificity and transcript abundance. Genes representing three 
developmental stages of P. falciparum were used: ring stage asexual trophozoites (TR, 
PF3D7_0501300), early-mid developing gametocytes (DG, PF3D7_1477700), and mid-late 
maturing gametocytes (MG, PF3D7_1438800) to enable the assessment of the development 
of gametocytes in malaria patients. The ring stage marker, TR, is a skeleton-binding protein 
associated with the infected erythrocyte skeleton that is highly expressed in ring stage TR 
compared with other life cycle stages. The early-mid gametocyte marker, DG, is an exported 
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protein with a PHISTa domain whereas the mid-early gametocyte marker, MG, is a 
conserved protein with an OST-HTH–associated domain. The functions of DG and MG are 
unknown, but DG is thought to be enriched specifically in asexual stages committed toward 
the sexual pathway22 whereas MG is highly expressed in gametocytes stages III–V.27 All 
three genes are intron-containing markers that enables the avoidance of genomic DNA 
amplification, by contrast to the established immature and mature gametocyte markers Pfs16 
and Pfs25. In addition, the frequency of gametocytemia in infections carrying gene variants 
associated with quinolone- and antifolate- drug resistance was assessed. The findings will 
inform the design of new strategies to more accurately dissect gametocyte production in 
patients and allow a more detailed analysis of the mechanisms involved in gametocyte 
maturation, which could lead to the development of transmission-blocking interventions. 
MATERIALS AND METHODS 
Ethics statement. 
The study obtained ethical clearance from the Ghana Health Service Ethics Review 
Committee in Accra (ID No: GHS-ERC 03/05/15) and the internal review board at the Weill 
Cornell Medical College in New York (IRB#1508016447). In addition, written informed 
consent and accent, in the case of children between 10 and 14 years, were obtained from 
individuals/parents/guardians before enrollment into the study. The study procedures, risks, 
and benefits were explained to all study participants and caregivers. Positive asexual parasites 
and gametocyte control samples for reverse transcriptase quantitative polymerase chain 
reactions were obtained from culture-adapted parasite isolates from among the study samples. 
Study area. 
This was a hospital-based study conducted between June and July 2016 in Ho in the Volta 
region, located in the southeastern part of Ghana where it borders Togo. The study area, 
environment, and malaria situation have been previously described.2 Plasmodium falciparum 
is responsible for almost all clinical malaria in this area. We had previously found that 
Plasmodium malariae was PCR-detectable in 2% of infections (5/211) in this area, and that 
all but one were coinfections with P. falciparum.2 To date, no Plasmodium ovale has been 
detected. The transmission of malaria in this area is variable but usually peaks one month 
after the start of each of the two rainy seasons, which take place from April to July and from 
September to November. The entomological inoculation rate for a nearby town, Hohoe, was 
estimated to be 65 infectious bites per person per year.28 
Patients and sample collection. 
Patients of all ages attending outpatient clinics at the Ho Polyclinic, the Ho Municipal 
Hospital, and Volta Regional Hospital were screened for malaria by rapid diagnostic tests 
(RDT) (Standard Diagnostics, Korea) and microscopy using finger-prick blood. Rapid 
diagnostic tests or microscopy-positive individuals, who gave their consent, were enrolled 
into the study to investigate the human host and parasite factors modulating the gametocyte 
development. Up to 5 mL of venous blood was collected in heparinized tubes from all 
participants for slide preparation, RNA preservation in Trizol (Invitrogen), parasite culture, 
and plasma separation. An additional blood sample of approximately 0.5 mL was collected in 
an EDTA tube for the determination of hematological parameters using a Sysmex 
hematology analyzer (Sysmex America). Briefly, plasma from venous blood was separated 
by centrifuging at 2,000 rpm for 10 minutes. The resulting parasite material was used for 
cryopreservation, parasite culture, and parasite nucleic acid (RNA) preservation in Trizol and 
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blood smears. Once samples were collected, participants were assisted to follow hospital 
procedures for disease management with no subsequent follow-up by us. Patients who had 
other illnesses in addition to malaria or had taken antimalarials in the preceding 14 days were 
excluded from the study. 
Assessment of asexual parasitemia and gametocytemia. 
Microscopy. 
Thin and thick smears were stained with 10% Giemsa for microscopic diagnosis and 
subsequent determination of parasitemia. Thin blood smears were fixed with methanol before 
Giemsa staining. Estimation of parasite densities was carried out by counting asexual 
parasites against 200 leukocytes whereas counting gametocytes against 500 leukocytes. Both 
parasite counts were converted to parasites per microliter by assuming a standard leukocyte 
count of 8,000 leukocytes in one microliter of blood, as already described.29,30 The slides 
were declared negative if no asexual parasites were seen after the examination of 100 
microscopic fields. 
Reverse transcriptase quantitative PCR. 
RNA extraction, DNase digests, and reverse transcription. 
Fifty microliters of whole blood samples obtained from patients were stored in 500 µL of 
Trizol at −80°C until RNA extraction. Total RNA from the samples was first extracted using 
the phenol–chloroform method, as previously described,31 and then purified using the AllPrep 
DNA/RNA Mini Kit (QIAGEN, Hilden, Germany) following the instructions from the 
manufacturer. The resulting RNA was treated with DNase (Invitrogen) and stored at −80°C. 
The SuperScript III First Strand Synthesis kit from Invitrogen was then used to synthesize the 
first-strand cDNA. 
Quantitative PCR assay. 
Amplification and quantification of stage-specific gene transcripts (rings 
PF3D7_0501300, early-mid gametocytes PF3D7_1477700, and mid-late gametocytes 
PF3D7_1438800)26 were performed using the QuantStudio5 (Applied Biosystems). 
Previously reported primer sets that target genes representing the aforementioned stages were 
used.26 All reactions were run in a total volume of 10 µL containing 1X PerfeCTa SYBR 
Green SuperMix, 0.5 µM of each of the forward and the reverse primers, and 2 µL of the 
target cDNA. The thermal profile for the reactions included 10 minutes at 95°C, 40 cycles of 
15 seconds at 95°C and 1 minute at 60°C. The specificities of the resulting products were 
analyzed using the dissociation curve and experiments with nonspecific products were 
repeated. All samples were run in triplicate and the mean Ct values were determined. 
Parasite-stage positivity was based on the absence or presence of the stage-specific RNA 
transcripts determined by the Ct values ≤ 35. A positive control RNA sample (GDVRH008) 
was obtained from a culture-adapted isolate of known asexual and gametocyte stage 
composition determined by microscopy. The control isolate, GDVRH008, was chosen 
because the patient was gametocyte-positive by microscopy and was readily inducible to 
produce gametocytes in vitro. This sample was positive also for all three stages of the 
parasite by RT-qPCR and at presentation had a gametocyte density of 16 parasites per 
microliter whereas the asexual parasite density was 26,160 parasites per microliter by 
microscopy. 
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Detection of single nucleotide polymorphisms (SNPs) in patient isolates. 
Genomic DNA extraction, nested PCR, and restriction enzyme digestion. 
The presence of antimalarial drug–associated SNPs in the clinical isolates was determined 
using PCR–RFLP. Briefly, DNA was extracted from all the samples using the AllPrep® 
DNA/RNA Mini Kit (QIAGEN) following the manufacturer’s instructions and then stored at 
–20°C. Both the outer and the nested PCRs were performed to amplify genomic regions that 
flank point mutations in the P. falciparum chloroquine resistance transporter gene (pfcrt) at 
position K76T; P. falciparum multidrug resistance gene one (pfmdr1) at positions N86Y and 
Y184F; P. falciparum dihydrofolate reductase gene (pfdhfr) at positions N51I, C59R, and 
S108N; and P. falciparum dihydropteroate synthetase (pfdhps) gene at positions A437G and 
K540E that have been implicated in antimalarial drug resistance. All reactions were 
performed in a total volume of 25 µL containing 1X of Maxima Hot Start Green PCR Master 
Mix (Thermo Scientific, United Kingdom) and 200 nM of each of the forward and reverse 
primers. A volume of 0.5 µL of the initial PCR product was used as template DNA in the 
nested PCR and, 5 µL of the resulting product was separated on an ethidium bromide–stained 
2% agarose gel before restriction digestion. PCR primer sets and cycling conditions for pfcrt 
and pfmdr1 were performed as previously reported32 whereas primers and conditions for 
pfdhfr and pfdhps also followed procedures already established.33 Using SNP-specific 
endonucleases (obtained from Thermo Scientific), 5 µL of the nested PCR product for each 
of the four genes was digested in a final volume of 15 µL. The restriction digest products 
were separated on an ethidium bromide–stained 2% agarose gel and the resulting gel was 
processed using the Amersham Imager 600 (General Electric). Laboratory-adapted strains of 
P. falciparum of known genotypes were used as controls for the wild-type and the mutant 
alleles. 
Data analysis. 
Descriptive statistics was calculated using Stata version 14.2 (TX) and Microsoft Excel 
for determining means, percentages, standard deviation, and plotting of graphs. Age and 
hemoglobin levels of patients were categorized into four groups each (< 5, 5–9, 10–16, and > 
16 years; and severe (< 8 g/dL), moderate (8–11 g/dL), mild (11–13 g/dL), and non-anemic 
(> 13 g/dL, respectively). For the purpose of logistic regression analysis, the severe anemia 
and moderate anemia groups were combined. These could therefore be considered as 
continuous or categorical variables depending on the analysis. The association between two 
continuous variables was assessed using Spearman’s rank correlation coefficient, whereas 
continuous and binary variables were assessed using Wilcoxon rank sum test. The linear 
logistic regression model was used to determine the association between age, hemoglobin, 
fever, and gametocyte carriage (MG). 
RESULTS 
Gametocyte carriage by microscopy. 
A total of 72 (Volta Region Hospital = 10, Ho Polyclinic = 16, and Ho Municipal 
Hospital = 46) RDT-positive individuals were enrolled and included during the 2-month 
study period (Table 1). Fever, temperature > 37.5°C, was recorded in 65% of all participants 
examined. Asexual parasite prevalence by microscopy was 91.67% (66/72) (Table 1). 
Gametocyte prevalence by microscopy was 12.5% (9/72) (Table 1). The study participants 
were somewhat evenly distributed among the different age categories, and all gametocyte 
carriers were either moderately or mildly anemic. The geometric mean asexual parasite 
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density by microscopy was 8,037.7 (95% CI: 5,075.9–12,727.8) parasites/µL whereas the 
geometric mean gametocyte density was 37.8 (95% CI: 24.7–58.0) parasites/µL (Table 1). 
Gametocyte carriage by RT-qPCR. 
Parasite stage-specific RT-qPCR was used to determine the presence of TR 
(PF3D7_0501300), DG (PF3D7_1477700), and MG (PF3D7_1438800) transcripts in each 
infection. Transcripts of the TR gene26 were present in all individuals, including the 6 RDT-
positive individuals who were negative for parasites by microscopy. The DG transcript was 
detected in 53% of individuals, whereas the MG transcript was detected in 36% (Figure 1). 
All nine individuals with detectable gametocytes by microscopy were positive for MG 
transcripts by RT-qPCR assay giving us a 100% specificity for microscopy but a significantly 
lower sensitivity than for RT-qPCR. Interestingly, four of the nine individuals with 
microscopically detectable gametocytes had no RT-qPCR signal for DG transcripts. The 
participants who were positive for either DG, MG or both transcripts (22/72) displayed mild 
or moderate anemia (32/38) but were evenly distributed between male and female patients 
(Table 2). The presence of the DG transcript is unexpected as DG are not found in the 
peripheral circulation and so should not have been captured in finger-prick sampling. 
However, the DG and MG transcripts have been previously characterized during gametocyte 
maturation in vitro,9,34 and it is unknown whether circulating sexually committed TR may 
also express the DG transcript in vivo. 
Prevalence of antimalarial (SNPs). 
The prevalence of known drug resistance–associated gene mutations in the parasite 
isolates was determined and related to gametocyte carriage in the participants. No isolate was 
found to contain the dhps-540 mutant allele, but the IRN triple mutant of pfdhfr was the 
predominant genotype at this locus (Figure 2). 
Sixty percent (3/5) and 48% (19/31) of the participants that harbored mutations in mdr1-
86 and mdr1-184, respectively, were positive for DG as determined by RT-qPCR. Similar 
observations were made when the prevalence of mdr1-86 and mdr1-184 mutations were 
compared with individuals harboring mature gametocytes (Table 3). Fifty-seven percent of 
the participants with the mutation dhps-437 had developing and mature gametocytes. All 
three mutations of dhfr tested were quite high, dhfr-51, dhfr-59, and dhfr-108, 91.07% 
(51/56), 85.96% (49/57), and 91.07% (51/56), respectively (Figure 2). Because of the high 
prevalence of the respective dhfr mutations, between 40% and 60% of participants expressing 
the different gametocyte markers had the mutations as seen already for dhps (Table 3). 
Age, hemoglobin levels, fever, and gametocytemia. 
Anemia was very common among our study participants. Based on the World Health 
Organization definition of anemia,35 we found that 87.5% of all our study participants had 
various degrees of anemia ranging from severe to mild anemia. Based on a linear logistic 
regression model, we observed that study participants between the ages of five (OR = 4.50, 
95% CI: 0.99–21.11) and 16 (OR = 5.00, 95% CI: 1.02–24.27) (Table 4) were more likely to 
carry MG transcripts compared with those younger than 5 years or older than 16 years. 
Moreover, mild anemia (OR = 1.88 [95% CI: 0.69–5.11] and no anemia (OR = 2.77 [95% CI: 
0.56–13.76] (Table 4) were possible predictors of gametocytemia compared with severely 
anemic participants. The prevalence of gametocytemia was less likely in patients with fever 
(OR = 0.74 [95% CI: 0.28–1.97] as compared with those without fever (Table 4). When the 
early-mid gametocyte marker was used, only age was found to be associated with 
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gametocytemia (5–9 years: OR = 3.27 CI: 0.65–16.38 and 10–16 years: OR = 2.05 CI: 0.44–
9.58). 
DISCUSSION 
The present study identified age, fever, and hemoglobin levels to be associated with 
carriage of MG transcripts, which may be a useful indicator of gametocyte carriage in malaria 
patients. Alleles associated with resistance to various antimalarial drugs were very common, 
including among participants with RT-qPCR evidence of gametocyte carriage. We also found 
higher estimates of gametocyte carriage by RT-qPCR than microscopy and showed that some 
individuals with DG mRNA did not have detectable MG mRNA levels. This was surprising 
because DG mRNA is assumed to indicate the presence of immature gametocytes, which are 
sequestered in tissues such as the bone marrow and therefore should not be detected in 
samples from the peripheral circulation of patients. However, in vitro studies have shown that 
DG’ transcripts can possibly come from sexually committed TR as they begin the asexual–
sexual stage transition.22 Therefore, these transcripts could indeed represent asexual parasites 
from the gametocyte commitment cycle which occurs before sexual-stage induction and 
differentiation. A longitudinal study is required to investigate the possibility of sexually 
committed TR in the peripheral circulation and their potential disappearance through 
sequestration. 
This study was able to identify 36% of participants as carriers of mature gametocytes 
through the detection of MG transcripts. In comparison, only 12.5% of individuals were 
identified as gametocyte carriers by microscopy. Several studies using molecular tools 
similarly detected higher levels of submicroscopic densities of gametocytes when compared 
with microscopy, and the gametocytes detected were even shown to establish infection in 
mosquitoes.36–38 In most of these studies, higher gametocyte densities were observed after 
drug treatment compared with the time of clinical presentation. artemisinin-based therapies 
reduce submicroscopic gametocytemia but do not completely prevent posttreatment 
transmission to mosquitoes in other studies.39 Our study participants were not followed up 
after treatment and it was not possible to estimate the level of submicroscopic gametocytemia 
following treatment. However, it is evident that microscopy heavily underestimates the 
proportion of individuals potentially capable of transmitting gametocytes to mosquitoes. 
Many factors are considered to influence commitment and production of gametocytes 
including genetic switching22,23 and environmental factors.40–42 Supplementation of serum, 
regardless of the malaria infection status of donors, has been shown to induce and improve 
gametocyte yields in in vitro gametocyte cultures.9,43 Clinical parameters such as age, the 
absence of fever, and hemoglobin levels have been previously shown to influence the degree 
of gametocytemia in individuals treated with different types of antimalarials.11,44–46 We found 
no strong relationship between age, hemoglobin levels, or fever with gametocytemia, but 
given our small sample size, these relationships will be investigated in larger studies in the 
future. However, the association we see with higher gametocyte prevalence in slightly older 
participants could be due to the level of clinical immunity they have acquired. Clinical 
immunity could play several roles including maintenance of low-grade asexual parasitemia 
and constant modulation of sexual development. Hemolysis of erythrocytes because of either 
high burden of parasitemia or effects of drugs have been suggested to trigger gametocyte 
production, but the degree of hemolysis was not investigated.47 This is consistent with our 
observation of gametocytemia in mildly anemic participants and agrees with other findings 
on the clinical correlates of gametocytemia.46 The high odds ratios for non-anemic, fever-free 
individuals is interesting and may suggest high prevalence of gametocytes in asymptomatics 
as already shown in other studies.46 
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Additional factors associated with patient gametocyte carriage include slow parasite 
clearance and carriage of drug resistance genotypes/alleles/polymorphisms.48,49 We found 
very high antimalarial-associated SNPs in some isolates but not others. Higher levels of dhps 
and dhfr alleles, which are associated with sulfadoxine–pyrimethamine (SP) resistance, were 
observed, but parasites carrying the crucial pfdhps-540E allele were absent among our study 
participants. In Ghana, SP is used for intermittent preventive treatment of malaria in pregnant 
women, which could contribute to the moderate levels of predicted SP resistance we and 
others have observed.50 On the contrary, low levels of chloroquine resistance–associated 
alleles were detected and may be an indication of the parasite population reverting to the 
sensitive genotype on removal of chloroquine from the market, as has been seen in other 
places.51 We however, did not find any significant correlation of the presence of these SNPs 
and gametocyte-specific transcripts in our patients probably because of the fact that most of 
the SNPs had a very high prevalence, and so our study was underpowered to test for such 
associations. 
CONCLUSION 
This study provides further evidence of the relationship between hemoglobin levels and 
the age of malaria patients and gametocyte carriage. In addition, it demonstrates an 
abundance of submicroscopic gametocytes as measured by RT-qPCR in untreated but sick 
populations providing ample opportunity for malaria transmission before treatment. The 
possibility that DG transcripts are present in sexually committed TR should be investigated in 
future studies. 
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FIGURE 1. Proportion of patients with PF3D7_1477700 and PF3D7_1438800 transcript-positive gametocytes as 
detected by stage-specific reverse transcriptase quantitative PCR: More than half of the participants were 
positive for PF3D7_1477700 mRNA, but not all these were positive for PF3D7_1438800 mRNA levels 
suggesting the presence of early maturing gametocytes. An even smaller proportion was positive for both 
PF3D7_1477700 and PF3D7_1438800 transcripts. This figure appears in color at www.ajtmh.org. 
FIGURE 2. Prevalence of antimalarial drug resistance-associated single nucleotide polymorphisms (SNPs): Each 
bar represents the proportion of the samples that display the mutant (blue) or wild-type (orange) amino acid at 
the position designated below the bar. Besides Plasmodium falciparum chloroquine resistance transporter 
(pfcrt)-76 and P. falciparum multidrug resistance gene one (Pfmdr1)-86 with mutations less than 10%, all other 
SNPs that we investigated were found to be saturated. No mutation in dhps-540 was found. This figure appears 
in color at www.ajtmh.org. 
TABLE 1 
Characteristics of patients at enrollment were as follows: Anemia was defined as severe (< 8 g/dL), moderate 
(8–11 g/dL), mild (11–13 g/dL), and non-anemic (> 13 g/dL) 
Parameter Value 
No 72 
Female: male 41:31 
Age in years, median (range) 13 (1–76) 
Axillary temperature, median in °C (range) 37.3 (36–40.6) 
Fever, % (n/N) 65 (47/72) 
Hemoglobin level, median in g/dL (range) 11.4 (3.4–16.2) 
Microscopy  
 Asexual parasite prevalence, % (n/N) 91.67 (66/72) 
 Geometric mean asexual parasite density/µL (95% CI) 
8,037.7 (5,075.9–
12,727.8) 
 Gametocyte prevalence, % (n/N) 12.5 (9/72) 
 Geometric mean gametocyte density/µL (95% CI) 37.8 (24.7–58.0) 
Reverse transcriptase quantitative PCR  
 PF3D7_0501300 RNA-positive ring stage prevalence, % (n/N) 100 (72/72) 
 PF3D7_1477700 RNA-positive early-mid gametocyte prevalence, % 
(n/N) 52.8 (38/72) 
 PF3D7_1438800 RNA-positive mid-late gametocyte prevalence % (n/N) 36.1 (26/72) 
Fever was defined as temperature > 37.5°C. 
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TABLE 2 
Clinical, demographic parameters and the composition of gametocytes as measured by reverse transcriptase 
quantitative PCR 
Parameter 
 
Early-mid gametocytes 
(N = 38) 
% Early-mid 
gametocytes 
Mid-late 
gametocytes (N = 
26) 
% Mid-late 
gametocytes 
Gender M 18 47 13 50 
 F 20 53 13 50 
Fever Yes 15 39 7 27 
 No 23 63 19 73 
Age < 5 years 6 16 6 23 
 5–10 years 12 32 8 31 
 10–16 years 9 24 7 27 
 > 16 years 11 29 5 19 
Anemia Moderate 16 42 11 42 
 Mild 16 42 11 42 
 Non-anemic 6 16 4 15 
M represents males whereas F represents females. 
TABLE 3 
Antimalaria-associated SNPs and the compositions of gametocytes 
SNP Number mutant 
Early-mid gametocytes 
(N = 38) 
% Early-mid 
gametocytes 
Mid-late 
gametocytes (N = 
26) 
% Mid-late 
gametocytes 
dhps_gly437 56 32 84 22 85 
dhfr_asn51ile 51 28 74 20 77 
dhfr_cys59arg 49 29 76 21 81 
dhfr_asn108 51 28 74 20 77 
mdr1_n86y 5 3 8 3 12 
mdr1_y184f 39 19 50 13 50 
pfcrt_k76t 3 2 5 0 0 
pfcrt = Plasmodium falciparum chloroquine resistance transporter; SNP = single nucleotide polymorphism. 
TABLE 4 
Possible predictors of gametocyte carriage among study participants: Using linear logistic regression, 
individuals between the ages of 5 and 16 years were more likely to carry gametocytes 
Risk factors for gametocytemia  Odds ratio (95% CI) 
Age 
< 5 years – 
5–10 years 4.50 (0.99–21.11) 
10–16 years 5.00 (1.02–24.27) 
> 16 years 1.32 (0.32–5.43) 
Fever No – Yes 0.74 (0.28–1.97) 
Hemoglobin 
Moderate anemia – 
Mild anemia 1.88 (0.69–5.11) 
Non-anemic 2.77 (0.56–13.76) 
Gametocytes were more prevalent in individuals without a history of fever and participants with mild anemia or 
those non-anemic had a higher chance of gametocytemia as compared with severe or moderately anemic 
participants. Severely anemic participants were included in the moderate anemic participants for analysis 
because they formed a small group. Anemia was defined as severe (< 8 g/dL), moderate (8–11 g/dL), mild (11–
13 g/dL) and non-anemic (> 13 g/dL). 
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SUPPLEMENTAL TEXT 
PRIMER SEQUENCES26† 
PF3D7_0501300 (ring) 
Reverse: TTGCTAGGTAATATCCTTTTCTTTTTCC 
Forward: GCAAAACAAGCCGTACATGTTG 
PF3D7_1477700 (early-mid gametocytes) 
Reverse: TTGGCCACACTGCTCTAGGA 
Forward: CTTATGTGCTGAATTTTGTGTTATGGT 
PF3D7_1438800 (mid-late gametocytes) 
Reverse: TCCCTGTGTTTTTGCTCATCTTC 
Forward: GTTACATTTCGACCCAGCATAAATT 
† Primer sequences were taken from Joice et al.26 
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